Current perspectives in antithrombotic therapy

Hamostaseologie

Volumn 21, Issue 3, 2001, Pages 82-96

  Fareed, J ^a   Hoppensteadt, D ^a   Iqbal, O ^a   Bick, R L ^a  

^a Layola University Medical Center   (United States)

Author keywords

Heparin; Ontithrombin ogents; Thrombolytics

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ABCIXIMAB; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; APROSULATE; APTAMER; ARGATROBAN; BENIPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CY 231; DANAPAROID; DEFIBROTIDE; DERMATAN SULFATE; DESMIN; DEXTRO PHENYLALANYLPROLYLARGININAL; EPTIFIBATIDE; FIBRINOLYTIC AGENT; GLYCOSAMINOGLYCAN; HEPARAN; HEPARIN; HIRUDIN; HIRULOG; INTIMITAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; N ACETYL 4 (AMINOIMINOMETHYL)PHENYLALANYL 2 CYCLOHEXYLGLYCYL 3 (1 METHYLPYRIDINIUM 3 YL) ALANYLLEUCYLPROLINAMIDE; NAPSAGATRAN; OP 370; OP 435; PENTASACCHARIDE; PENTOSAN POLYSULFATE; PI 88; SULEPAROIDE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 337; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID;

ANTICOAGULANT THERAPY; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; FAMILIAL DISEASE; HUMAN; MORTALITY; PARALYSIS; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; THROMBOCYTE ANOMALY; THROMBOSIS; UNITED STATES; VISUAL IMPAIRMENT;

EID: 0034862672     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619515     Document Type: Review

References (81)

1. Newer approaches to the pharmacologic management of acute myocardial infarction
2. Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs
3. Chemical and biochemical heterogeneity in low molecular weight heparins: Implications for clinical use and standardization
4. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
5. Comparison of subcutaneous standard low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
6. The development of low molecular weight heparins for clinical use
7. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
8. Heparin induced thrombocytopenia
9. Heparin induced thrombocytopenia, thrombosis and haemorrhage
10. Heparin osteoporosis
11. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration
12. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
13. Enoxaparin versus dextran 70 in the prevention of post-operative deep vein thrombosis after total hip replacement. A Danish multicenter study
14. Comparison of low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
15. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine
16. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine
17. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial
18. Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and Fragmin
19. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement
20. Adjusted versus fixed subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement
21. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement
22. Efficacy and safety of low molecular weight heparin (CY 216) in preventing postoperative venous thromboembolism: A cooperative study
23. An overview of clinical trials with low molecular weight heparin fractions
24. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery
25. Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin
26. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin
27. Role of endothelial cell surface heparin-like polysaccharides
28. Pharmacology of sulfomucopoly-saccharides in atherosclerosis prevention and treatment
29. An overview of non-heparin glycosaminoglycans as antithrombotic agents
30. Heparan sulfate: Efficacy and safety in patients with chronic venous insufficiency
31. Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations
32. Thromboprophylaxis in patients with hip fractures. A prospective, randomized, comparative study between Org 10172 and dextran 70
33. Neue antithrombotika: Ein überblick
34. A controlled clinical experiment 〉within subjects〈 with heparan sulfate in intermittent claudication
35. Dermatan sulphate in haemodialysis
36. Dermatan sulphate in acute leukaemia
37. An objective perspective on recombinant hirudin: A new anticoagulant and antithrombotic agent
38. A strategy for a rational approach to designing synthetic selective inhibitors
39. Effect of argipidine (MD-805) on blood coagulation
40. Synthetic anticoagulants
41. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation
42. Clinical applications of the synthetic thrombin inhibitor, argatroban (MD-805)
43. Phase I studies on inogatran, a new selective thrombin inhibitor
44. Peptide aldehyde inhibitors of the fibrinogen-thrombin reaction
45. Highly active and selective anti-coagulants D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H
46. Pharmacological survey of recombinant hirudin
47. Design and characterization of hirulogs. A novel class of bivalent peptide inhibitors of thrombin
48. Recombinant hirudin: A perspective
49. Novel antithrombotic approaches to coronary artery disease
50. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
51. HIT, HITT and desulfatohirudin: Look before you leap
52. The effect of burn wound size on hemostasis: A correlation of the hemostatic changes to the clinical state
53. Prophylactic continuous infusion (CI) antithrombin III (AT-III) for prevention of regimen related toxicity (RRT) following bone marrow transplantation (BMT)
54. Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT) - Results of a pilot study
55. Prevention of venous thromboembolism
56. Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency
57. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors
58. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
59. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
60. Factor Xa inhibitors in the control of thrombogenesis
61. Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development
62. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states
63. Platelet membrane glycoprotein IIb/IIIa member of a family of RGD specific adhesion receptors
64. GPIIb/IIIa the responsive integrin
65. Inhibition of platelet function with synthetic peptide designed to be high affinity antagonist of fibrinogen binding to platelets
66. Antiplatelet antibody [7E3 f(ab′)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model
67. Selection of single-stranded DNA molecules that bind and inhibit human thrombin
68. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution
69. The single-stranded DNA aptamer binding-site of human thrombin
70. High-affinity RNA ligands to human a-thrombin
71. Pharmacologic profiling of defibrotide in experimental models
72. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro
73. Thrombolytic drugs offer new therapeutic options
74. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
75. Synthetic and recombinant antithrombin drugs
76. Recombinant TFPI and variants: Potential implications in the treatment of cardiovascular disorders
77. Nucleic acid therapeutics: State of the art and future prospects
78. Treatment of severe venoocclusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population
79. Heparin and cancer
80. Antithrombin agents as anti-coagulants and antithrombotics. Implications in drug development
81. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes